These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 17052783)

  • 1. Mitral heart disease due to cabergoline.
    Martin M; Iglesias-Cubero G; Diaz Molina B; Moris De la Tassa C
    Int J Cardiol; 2007 Jan; 114(1):e7-8. PubMed ID: 17052783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mitral valve replacement for cabergoline-related severe mitral regurgitation].
    Hanada T; Shimizu K; Murakami R; Ota T; Okada S; Inoue S; Hiroe K; Higaki Y; Oda T
    Kyobu Geka; 2007 Oct; 60(11):1018-21. PubMed ID: 17926907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline-related severe restrictive mitral regurgitation.
    Pinero A; Marcos-Alberca P; Fortes J
    N Engl J Med; 2005 Nov; 353(18):1976-7. PubMed ID: 16267335
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's drugs linked to heart valve trouble.
    Harv Heart Lett; 2007 Apr; 17(8):7. PubMed ID: 17402160
    [No Abstract]   [Full Text] [Related]  

  • 6. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
    Sato T; Kikuchi A; Onoue N; Hiramoto T; Oumi M; Onodera J
    Rinsho Shinkeigaku; 2008 Jul; 48(7):486-91. PubMed ID: 18717182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
    Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
    J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment.
    Luedde M; Helmke B; Katus HA; Frey N
    Int J Cardiol; 2009 Apr; 133(3):e97-8. PubMed ID: 18191474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
    Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
    Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
    Fietzek UM; Riedl L; Ceballos-Baumann AO
    Parkinsonism Relat Disord; 2012 Jun; 18(5):654-6. PubMed ID: 21908226
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of iatrogenic severe mitral regurgitation.
    D'Aloia A; Piovanelli B; Rovetta R; Bonadei I; Vizzardi E; Curnis A; Metra M
    Monaldi Arch Chest Dis; 2013 Sep; 80(3):133-6. PubMed ID: 24818320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
    Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cabergoline in hyperprolactinemia and valvular heart disease].
    Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
    Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
    Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
    Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reaction suggested by a clinical vignette.
    Finestone AJ
    Clin Interv Aging; 2011; 6():199. PubMed ID: 21822375
    [No Abstract]   [Full Text] [Related]  

  • 18. Cabergoline and the risk of valvular lesions in endocrine disease.
    Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
    Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
    Lökk J
    Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
    Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.